BURLINGAME, CA, USA I November 11, 2012 I Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen’s proprietary antibody technology platform to enter human trials.
APX003/BD0801 is being developed in China through an active partnership between Apexigen and Simcere. Apexigen has collaborated with Simcere to add its antibody development expertise and experience to the advancement of the APX003/BD0801 program. This approval marks the success of the dedicated work of the collaboration team to file and defend an IND application, and initiates the next phase of collaboration in clinical development.
"We’re very pleased to see the IND approval for APX003/BD0801. This is an important milestone for our collaboration with Simcere and for proof-of-concept of our antibody technology platform" said Dr. Xiaodong Yang, President & CEO. "We look forward to continuing the collaboration with Simcere and advancing AXP003/BD0801 into clinical development."
APX003/BD0801 is a humanized monoclonal antibody directed against VEGF and is under development for the treatment of multiple malignancies.
About Apexigen, Inc.
Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease targets.
Apexigen is actively pursuing product development, both by itself and in collaboration with partners, with a focus in oncology. The company’s product portfolio is comprised of humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease.
Collaboration is an important aspect of Apexigen’s business model. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform. Additional information is available at www.apexigen.com.
SOURCE: Apexigen
Post Views: 109
BURLINGAME, CA, USA I November 11, 2012 I Apexigen, an emerging biopharmaceutical company dedicated to the discovery and development of best-in-class therapeutic monoclonal antibodies, announced today that its partner, Simcere Pharmaceutical Group (SCR) of Nanjing, received approval from the State Food and Drug Administration of China to begin first-in-man trials with APX003, which is also known as BD0801, for the treatment of cancer. With this approval, APX003/BD0801 becomes the first humanized monoclonal antibody derived from Apexigen’s proprietary antibody technology platform to enter human trials.
APX003/BD0801 is being developed in China through an active partnership between Apexigen and Simcere. Apexigen has collaborated with Simcere to add its antibody development expertise and experience to the advancement of the APX003/BD0801 program. This approval marks the success of the dedicated work of the collaboration team to file and defend an IND application, and initiates the next phase of collaboration in clinical development.
"We’re very pleased to see the IND approval for APX003/BD0801. This is an important milestone for our collaboration with Simcere and for proof-of-concept of our antibody technology platform" said Dr. Xiaodong Yang, President & CEO. "We look forward to continuing the collaboration with Simcere and advancing AXP003/BD0801 into clinical development."
APX003/BD0801 is a humanized monoclonal antibody directed against VEGF and is under development for the treatment of multiple malignancies.
About Apexigen, Inc.
Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease targets.
Apexigen is actively pursuing product development, both by itself and in collaboration with partners, with a focus in oncology. The company’s product portfolio is comprised of humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease.
Collaboration is an important aspect of Apexigen’s business model. At present, seven corporate collaborations are in place, representing both product development collaborations and antibody technology collaborations. Through the building of successful collaborations, Apexigen is able to develop a broad base of antibody products and promote wider use of its antibody technology platform. Additional information is available at www.apexigen.com.
SOURCE: Apexigen
Post Views: 109
